OBJECTIVE: To observe the therapeutic effect and relevant mechanism of shuxuening Injection (SI) in treating @entity1 with active @entity31 ( @entity31 ). METHODS: Totally 91 @entity1 with active @entity31 were randomly assigned to 2 groups, 44 in the control group and 47 in the treatment group. @entity1 in the control group received routine treatment, while @entity1 in the treatment group additionally received intravenous injection of SI (15 mL), twice daily for 14 days in total. Colonoscopy was performed before and after treatment. The therapeutic effect was assessed by Mayo scoring system and the grading of activities evaluated by Baron endoscope. Serum levels of @entity650 and @entity310 were detected by ELISA. The activity of SOD was detected by @entity3624 oxidase method. The content of @entity1865 was detected by @entity4466 (TBA). Besides, 20 healthy subjects were recruited as the healthy control group. RESULTS: Totally 82 @entity1 completed the study (40 in the control group and 42 in the treatment group). There was no statistical difference in serum levels of @entity650 , @entity310 , SOD, @entity1865 , the Mayo score and endoscope grading between the two groups before treatment (P >0. 05). Compared with the healthy control group, serum levels of @entity650 , @entity310 , @entity1865 significantly increased (P <0.01), and the serum SOD level decreased (P < 0. 05) in the treatment grup and the control group before treatment. Compared with before treatment in the same group, serum levels of @entity650 , @entity310 , @entity1865 , the Mayo score and endoscope grading all decreased in the treatment group and the control group after treatment (P <0. 01, P <0. 05). Compared with the control group after treatment, serum levels of @entity650 , @entity310 , @entity1865 , the Mayo score and endoscope grading all decreased (P <0.01, P <0.05), the serum SOD level increased (P <0.05) in the treatment group after treatment. The serum SOD level was obviously negative correlated with serum levels of @entity650 , @entity310 , Mayo score, and endoscope score (r = -0. 621, -0.638, -0. 509, -0.787, P <0.01). The serum @entity1865 level was obviously positive correlated with serum levels of @entity650 , @entity310 , Mayo score, and endoscope score (r =0.711, 0. 882, 0. 525, 0. 639, P <0.01). CONCLUSION: SI could improve inflammatory injury and clinical symptoms of @entity1 with active @entity31 , and its mechanism might be associated with antioxidant and scavenging @entity26 free radicals.

[Shuxuening injection combined with routine therapy in treating @entity1 with active XXXX : an analysis of efficacy ].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity650 :: ('3569', 'Gene') :: ['IL-6'] @entity310 :: ('7124', 'Gene') :: ['TNF-a'] @entity3624 :: ('MESH:D019820', 'Chemical') :: ['xanthine'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC'] @entity4466 :: ('MESH:C029684', 'Chemical') :: ['thiobarbituricacid'] @entity1865 :: ('CHEBI:566274', 'Chemical') :: ['MDA']
@entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']
